Search

Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Resectable Head and Neck Cancer

NICE has published final technology appraisal guidance TA1145 recommending pembrolizumab (Keytruda) for the neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma in adults. The guidance includes a commercial access agreement with NHS pricing arrangements. NHS commissioners and providers are expected to fund the treatment in accordance with NICE recommendations.

Prospective Exploration of Vascular Complications Associated With Immune Checkpoint Inhibitors

NIH registered an observational study (NCT07535944) on ClinicalTrials.gov to explore vascular complications associated with immune checkpoint inhibitors (ICIs). The study will evaluate the vascular impact of ICIs such as nivolumab, pembrolizumab, and atezolizumab in cancer patients. ICIs have been linked to immune-mediated toxicities affecting various organ systems, including the cardiovascular system, though vascular complications remain poorly understood.